The Lists mobile-friendly digital edition can be accessed here.
Iowa IV in Des Moines explains
Across all six studies, the safety findings were consistent: no serious adverse events, no immunogenic responses, no changes in IGF-1, no glucose or insulin disruption
The most commonly reported side effects are mild and transient, including injection site reactions (redness, slight swelling, or tenderness), mild headaches during the initial days of use, and occasional dizziness or lightheadedness, particularly when starting the peptide
By FormBlends Editorial Research|Source reviewed by FormBlends Medical Team|| Source Reviewed Written by FormBlends Editorial Research Checked against primary sources by FormBlends Medical Team In This Article This article is part of our Peptide Therapy collection
No evidence indicates BPC-157 causes cancer, but individuals with active malignancies or high cancer risk should exercise caution